Status:
COMPLETED
A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
This study will determine the efficacy and safety of RO4917838 in patients with schizophrenia who are stable on current antipsychotic treatment (olanzapine, que tiapine, risperidone, paliperidone or a...
Eligibility Criteria
Inclusion
- adult patients, 18-60 years of age;
- diagnosis of schizophrenia (based on screening tests);
- outpatients, with no hospitalization for worsening of schizophrenia within 3 months;
- medically and psychiatrically stable over prior 1 month and psychiatrically stable without symptom exacerbation within prior 3 months;
- currently taking no more than 2 antipsychotic drugs.
Exclusion
- began a new non-medication treatment for schizophrenia or other psychiatric condition within last 3 months;
- on \>1 antidepressant, or a change in dose of antidepressant within 3 months;
- alcohol or substance abuse or dependence within 3 months;
- has previously received RO4917838.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2010
Estimated Enrollment :
323 Patients enrolled
Trial Details
Trial ID
NCT00616798
Start Date
March 1 2008
End Date
February 1 2010
Last Update
June 24 2014
Active Locations (73)
Enter a location and click search to find clinical trials sorted by distance.
1
Granada Hills, California, United States, 91344
2
Los Angeles, California, United States, 90033
3
Oceanside, California, United States, 92056
4
Torrance, California, United States, 90502